SCHEMBL6897562

SCHEMBL6897562

CC(C)(C)OC(=O)C(OCc1ccccc1)[C@@H](N)Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.51
SLC1A2 P43004 2/20 0.51
SLC1A1 P43005 2/20 0.51
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
LTA4H P09960 3/20 0.46
LAP3 P28838 1/20 0.45
SYK P43405 1/20 0.44
ITGA4 P13612 1/20 0.44
ITGB7 P26010 1/20 0.44
SLC7A5 Q01650 2/20 0.42
ATM Q13315 1/20 0.41
ANPEP P15144 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL2848667 0.97 SLC1A3 (0.49) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL9095387 0.84 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL9095855 0.84 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL5275264 0.83 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL3287115 0.83 SLC1A2 (0.54) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL4659671 0.81 LTA4H (0.58) LTA4HLAP3ITGA4ITGB7SLC7A5
SCHEMBL3915987 0.81 LTA4H (0.58) LTA4HLAP3ITGA4ITGB7SLC7A5
SCHEMBL3927263 0.81 LTA4H (0.58) LTA4HLAP3ITGA4ITGB7SLC7A5
SCHEMBL2848679 0.81 LTA4H (0.58) LTA4HLAP3ITGA4ITGB7SLC7A5
SCHEMBL4730834 0.81 ITGA4 (0.48) SLC1A3SLC1A2SLC1A1LTA4HLAP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH SLC1A3 3946/4885SLC1A2 4225/4885SLC1A1 3771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.